249 related articles for article (PubMed ID: 21646298)
21. Characterization of monoclonal antibodies directed against the gp46 of human T-cell leukemia virus type I.
Edouard E; Legrand E; Astier-Gin T; Dalibart R; Geoffre S; Dalbon P; Guillemain B; Londos-Gagliardi D
Leukemia; 1994 Apr; 8 Suppl 1():S60-4. PubMed ID: 7512182
[TBL] [Abstract][Full Text] [Related]
22. Influence of amino acid substitutions on antigenicity of immunodominant regions of the HTLV type I envelope surface gylcoprotein: a study using monoclonal antibodies raised against relevant peptides.
Londos-Gagliardi D; Jauvin V; Armengaut MH; Astier-Gin T; Goetz M; Huet S; Guillemain BJ
AIDS Res Hum Retroviruses; 1999 Jul; 15(10):909-20. PubMed ID: 10408728
[TBL] [Abstract][Full Text] [Related]
23. Cervicovaginal synthesis of IgG antibodies to the immunodominant 175-199 domain of the surface glycoprotein gp46 of human T-cell leukemia virus type I.
Bélec L; Georges-Courbot MC; Georges A; Mohamed AS; Londos-Gagliardi D; Hallouin MC; Hocini H; Guillemain B
J Med Virol; 1996 Sep; 50(1):42-9. PubMed ID: 8890040
[TBL] [Abstract][Full Text] [Related]
24. Epitope mapping of human monoclonal antibodies recognizing conformational epitopes within HTLV type 1 gp46, employing HTLV type 1/2 envelope chimeras.
Hadlock KG; Yang Q; Rowe J; Foung SK
AIDS Res Hum Retroviruses; 2002 Jan; 18(1):57-70. PubMed ID: 11804557
[TBL] [Abstract][Full Text] [Related]
25. Rapid syncytium formation between human T-cell leukaemia virus type-I (HTLV-I)-infected T-cells and human nervous system cells: a possible implication for tropical spastic paraparesis/HTLV-I associated myelopathy.
Mor-Vaknin N; Turgeman H; Torgeman A; Wolfson M; Huleihel M; Aboud M
Cell Biol Int; 1998; 22(2):95-103. PubMed ID: 9878096
[TBL] [Abstract][Full Text] [Related]
26. Glycosylation-dependent peptide antigenic determinants of env gp46 HTLV-1.
Kaumaya PT; Conrad SF; DiGeorge AM; Lairmore MD
Leukemia; 1995 Oct; 9 Suppl 1():S133-8. PubMed ID: 7475306
[TBL] [Abstract][Full Text] [Related]
27. Rapid generation of antibodies against the HTLV-II external envelope protein by growth of mouse plasmacytomas in SCID mice.
Li QX; Camerini D; Kuritzkes DR; Chen IS
Virology; 1995 Dec; 214(2):680-4. PubMed ID: 8553576
[TBL] [Abstract][Full Text] [Related]
28. Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus.
Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
Biochem Biophys Res Commun; 2001 Nov; 289(1):1-6. PubMed ID: 11708767
[TBL] [Abstract][Full Text] [Related]
29. Generation and characterization of monoclonal antibodies against multiple epitopes on the C-terminal half of envelope gp46 of human T-cell leukemia virus type-I (HTLV-I).
Tanaka Y; Yasumoto M; Nyunoya H; Ogura T; Kikuchi M; Shimotohno K; Shiraki H; Kuroda N; Shida H; Tozawa H
Int J Cancer; 1990 Oct; 46(4):675-81. PubMed ID: 1698731
[TBL] [Abstract][Full Text] [Related]
30. Heat shock cognate protein 70 is a cell fusion-enhancing factor but not an entry factor for human T-cell lymphotropic virus type I.
Fang D; Haraguchi Y; Jinno A; Soda Y; Shimizu N; Hoshino H
Biochem Biophys Res Commun; 1999 Aug; 261(2):357-63. PubMed ID: 10425190
[TBL] [Abstract][Full Text] [Related]
31. Identification of HTLV-1-specific CTL directed against synthetic and naturally processed peptides in HLA-B*3501 transgenic mice.
Schönbach C; Nokihara K; Bangham CR; Kariyone A; Karaki S; Shida H; Takatsu K; Egawa K; Wiesmüller KH; Takiguchi M
Virology; 1996 Dec; 226(1):102-12. PubMed ID: 8941327
[TBL] [Abstract][Full Text] [Related]
32. HTLV-1 and -2 envelope SU subdomains and critical determinants in receptor binding.
Kim FJ; Manel N; Garrido EN; Valle C; Sitbon M; Battini JL
Retrovirology; 2004 Dec; 1():41. PubMed ID: 15575958
[TBL] [Abstract][Full Text] [Related]
33. Comparison of antigenic sites of the envelope glycoprotein of the Iranian isolate of human T-cell leukemia virus type 1 with different subtypes of the virus.
Mohabatkar H; Sadeghi S
Saudi Med J; 2006 Aug; 27(8):1121-4. PubMed ID: 16883437
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I).
Conrad SF; Byeon IJ; DiGeorge AM; Lairmore MD; Tsai MD; Kaumaya PT
Biomed Pept Proteins Nucleic Acids; 1995; 1(2):83-92. PubMed ID: 9346859
[TBL] [Abstract][Full Text] [Related]
35. Chimeric synthetic peptides from the envelope (gp46) and the transmembrane (gp21) glycoproteins for the detection of antibodies to human T-cell leukemia virus type II.
Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
Biochem Biophys Res Commun; 2001 Nov; 289(1):7-12. PubMed ID: 11708768
[TBL] [Abstract][Full Text] [Related]
36. Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans.
Piñon JD; Klasse PJ; Jassal SR; Welson S; Weber J; Brighty DW; Sattentau QJ
J Virol; 2003 Sep; 77(18):9922-30. PubMed ID: 12941902
[TBL] [Abstract][Full Text] [Related]
37. Distinct mechanisms of neutralization by monoclonal antibodies specific for sites in the N-terminal or C-terminal domain of murine leukemia virus SU.
Burkhart MD; Kayman SC; He Y; Pinter A
J Virol; 2003 Apr; 77(7):3993-4003. PubMed ID: 12634359
[TBL] [Abstract][Full Text] [Related]
38. Expression of HTLV-I Env and Tax recombinant peptides in yeast: identification of immunogenic domains.
Noraz N; Benichou S; Madaule P; Tiollais P; Vernant JC; Desgranges C
Virology; 1993 Mar; 193(1):80-8. PubMed ID: 7679862
[TBL] [Abstract][Full Text] [Related]
39. Elimination of human T cell leukemia virus type-1-infected cells by neutralizing and antibody-dependent cellular cytotoxicity-inducing antibodies against human t cell leukemia virus type-1 envelope gp46.
Tanaka Y; Takahashi Y; Tanaka R; Kodama A; Fujii H; Hasegawa A; Kannagi M; Ansari AA; Saito M
AIDS Res Hum Retroviruses; 2014 Jun; 30(6):542-52. PubMed ID: 24524420
[TBL] [Abstract][Full Text] [Related]
40. The neutralizing function of the anti-HTLV-1 antibody is essential in preventing in vivo transmission of HTLV-1 to human T cells in NOD-SCID/γcnull (NOG) mice.
Saito M; Tanaka R; Fujii H; Kodama A; Takahashi Y; Matsuzaki T; Takashima H; Tanaka Y
Retrovirology; 2014 Aug; 11():74. PubMed ID: 25163482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
